Recital 12, Regulation (EU) 2023/948

In forcesince 12 May 2023

The Commission assessed all the information provided by the applicant and considered that the applicant has sufficiently substantiated the fulfilment of the requirements laid down in Article 26(2) of Regulation (EU) 2015/2283. Therefore, the scientific studies and data submitted in support of the application, namely, mass spectrometry (‘MS’), nuclear magnetic resonance (‘NMR’) and a high-performance anion-exchange chromatography with pulsed amperometric detection (‘HPAEC-PAD’) method validation and the results for the determination of the identity of 6′-SL and of the carbohydrate by-products present in the novel food; the description and certificates of deposition of the genetically modified 6′-SL sodium salt production and optional degradation strains; the real time quantitative polymerase chain reaction (‘qPCR’) system and method validation reports for the genetically modified 6′-SL sodium salt production and optional degradation strains; the bacterial reverse mutation test with 6′-SL sodium salt; the in vitro mammalian cell micronucleus test with 6′-SL sodium salt; the 7-day dose range finding oral toxicity study in rats with 6′-SL sodium salt; and, the 90-day oral toxicity study in rats with 6′-SL sodium salt, should be protected in accordance with Article 27(1) of Regulation (EU) 2015/2283. Accordingly, only the applicant should be authorised to place 6′-SL sodium salt produced with derivative strains of Escherichia coli BL21(DE3) on the market within the Union during a period of five years from the entry into force of this Regulation.